UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 11, 2026

GMR Solutions Inc.

(Exact name of registrant as specified in its charter)

4400 Hwy 121, Suite 700,
Lewisville, TX 75056
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (972) 459-4919

Not applicable
(Former name or former address, if changed since last report.)

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

On September 11, 2026, Global Medical Response, Inc. (“GMR, Inc.”), a subsidiary of GMR Solutions Inc. (the “Company”), announced it has received binding commitments from lenders sufficient to complete a repricing transaction with respect to GMR, Inc.’s existing first lien term loan facility. A copy of the press release is attached hereto as Exhibit 99.1 and is hereby incorporated by reference.

The repricing transaction is expected to amend GMR, Inc.’s existing first lien term loan. In connection with the repricing transaction, GMR, Inc. expects to voluntarily prepay approximately $200 million of the outstanding first lien term loan. The amended term loan is expected to bear interest at a lower applicable interest rate margin than GMR, Inc.’s existing term loan. The applicable interest rate margin to the SOFR rate published by CME Group Benchmark Administration Limited (“SOFR”) will decrease from +3.25% to +2.75%, representing a reduction of approximately 50 basis points. The Company expects the repricing transaction and related debt repayment to result in approximately $28 million of annual cash interest expense savings.

The Company believes the transaction is consistent with its capital allocation strategy of using cash generated by the business to reduce indebtedness, lower borrowing costs and support its long-term deleveraging objectives.

The Company currently expects the repricing transaction to close on or about September 17, 2026, subject to the execution of definitive documentation and satisfaction of customary closing conditions.

This Current Report on Form 8-K contains forward-looking statements, including statements regarding the expected consummation, timing and benefits of the repricing transaction. Actual results may differ materially from those expressed or implied by these forward-looking statements as a result of various risks and uncertainties, including the failure to satisfy customary closing conditions or complete the transaction on the anticipated terms or timetable. The Company undertakes no obligation to update any forward-looking statements except as required by law.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized.

ATTACHMENTS / EXHIBITS

EXHIBIT 99.1

XBRL TAXONOMY EXTENSION SCHEMA

XBRL TAXONOMY EXTENSION LABEL LINKBASE

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

IDEA: R1.htm

IDEA: FilingSummary.xml

IDEA: MetaLinks.json

IDEA: tm2625250d1_8k_htm.xml